NCT02326142View on ClinicalTrials.gov

A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2017

Conditions
Preterm Labor
Interventions
DRUG

OBE001

OBE001 dispersible tablets for a single oral dose a day for up to 7 days.

DRUG

Placebo

Placebo dispersible tablets for a single oral dose a day for up to 7 days.

Trial Locations (23)

Unknown

Brussels

Leuven

Liège

Bayreuth

Düsseldorf

Tübingen

Ulm

Bialystok

Chorzów

Lodz

Ruda Śląska

Warsaw

Barcelona

El Palmar

Madrid

Vitoria-Gasteiz

Zaragoza

Basel

Bern

Geneva

Lausanne

Leeds

London

Sponsors

Lead Sponsor

ObsEva SA
All Listed Sponsors
lead

ObsEva SA

INDUSTRY